Issue Information
21 December 2016
Issue Information
21 December 2016
Reply:
Gonzalo Sapisochin, Jordi Bruix – 20 December 2016
Ignore reality but not the consequences of its ignorance: Broaden guidelines in surgery of hepatocellular carcinoma
Demetrios Moris, Evangelos Felekouras – 20 December 2016
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.
The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
Patricia T. Vietheer, Irene Boo, Jun Gu, Kathleen McCaffrey, Stirling Edwards, Catherine Owczarek, Matthew P. Hardy, Louis Fabri, Rob J. Center, Pantelis Poumbourios, Heidi E. Drummer – 20 December 2016 – A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type‐specific immune responses with limited potency against heterologous viral strains and genotypes.
Reply:
Benjamin Lelouvier, Florence Servant, Michael Courtney, Rémy Burcelin, Jacques Amar – 20 December 2016
Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation
Rahul Gupta, Jyoti Gupta – 20 December 2016
Long‐term outcome in liver transplantation candidates with portopulmonary hypertension
Laurent Savale, Caroline Sattler, Audrey Coilly, Filoména Conti, Sébastien Renard, Claire Francoz, Hélène Bouvaist, Cyrille Feray, Patrick Borentain, Xavier Jaïs, David Montani, Florence Parent, Caroline O'Connell, Philippe Hervé, Marc Humbert, Gérald Simonneau, Didier Samuel, Yvon Calmus, Christophe Duvoux, François Durand, Jean Charles Duclos‐Vallée, Olivier Sitbon – 20 December 2016 – Portopulmonary hypertension (PoPH) is diagnosed in 2‐6% of liver transplantation (LT) candidates. We studied outcomes of candidates for LT suffering from PoPH.